http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#Head
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#assertion
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#provenance
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#pubinfo
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#assertion
http://purl.obolibrary.org/obo/DOID_4362
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_4362
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01030
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
http://www.w3.org/2000/01/rdf-schema#label
topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy as a single agent 1 1 patients with small cell lung cancer slsc platinum sensitive disease who progressed at least 6 days after initiation of first line chemotherapy as a single agent 1 2 patients with stage iv b recurrent or persistent cervical cancer which is not amenable to curative treatment in combination with cisplatin 1 3 topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with small cell lung cancer sclc with platinum sensitive disease who progressed at least 6 days after initiation of first line chemotherapy topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv b recurrent or persistent cervical cancer of the cervix not amenable to curative treatment
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB01030
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#provenance
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#pubinfo
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#sig
http://purl.org/nanopub/x/hasSignature
A1bcyH9iLCy/J+XwgmdOvp5oWB51g6GzeamPPJapNkZVWc1D2lkwXmrmihK+/31QVu5XzKOTvMsMihlMdGKonQ3MPtn4b4ZAaao9GeS+4LVae6Iavlzs9rLTeFWvZC21cSEox1Dud4JGKPGJK/wfJfw7LgiSrmjRjqTWoGFw6GY=
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
http://purl.org/dc/terms/created
2021-07-03T14:12:13.725+02:00
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAXg36EOYecQ6V3sA5LY5dRzN7GSlpknhS3bEtas3rIMA
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs